Compare › semaglutide vs liraglutide
semaglutide vs liraglutide
Both semaglutide and liraglutide are approved in the US, so the useful differences between them are which conditions each is approved for and what is still under study. semaglutide has 429 trials on file here and liraglutide 290, which is a rough measure of how far each programme has been pushed.
A side-by-side of what the public record holds on each: regulatory status in the US and EU, how much trial work is running, and which conditions each is being studied in. No efficacy comparison: head-to-head claims belong to the trials that made them, not to us.
| semaglutide | liraglutide | |
|---|---|---|
| Status | marketed | marketed |
| Target | GLP-1 | GLP-1 |
| Route | SC/oral | SC |
| Sponsor | Novo Nordisk | Novo Nordisk |
| US brand names | OZEMPIC, RYBELSUS, WEGOVY, WEGOVY FLEXTOUCH, WEGOVY HD | LIRAGLUTIDE, SAXENDA, VICTOZA, XULTOPHY 100/3.6 |
| First FDA approval | 2017-12-05 | 2010-01-25 |
| EU authorisation | Ozempic, Rybelsus, Wegovy | Saxenda, Victoza, Xultophy |
| FDA actions on file | 52 | 77 |
| Active trials | 214 | 17 |
| Active phase 3 | 75 | 2 |
| Participants enrolled | 98,857 | 2,721 |
| Results scheduled | 96 | 3 |
| Supply records | 3 | 11 |
Where they are being studied
Both: Atrial fibrillation; Cardiovascular disease; Diabetes (unspecified); Diabetic kidney disease; Heart failure; Hypertension; MASH / NAFLD; Metabolic syndrome; Neurodegenerative disease; Obesity & overweight; Obstructive sleep apnea; Polycystic ovary syndrome; Prediabetes; Psychiatric conditions; Substance use; Type 1 diabetes; Type 2 diabetes
semaglutide only: Alcohol use disorder; Cancer; Chronic kidney disease
liraglutide only: Osteoarthritis